Q-omics provides the consensus-scored TECPR2 profile across patient tissues and cancer cell-line models. TECPR2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TECPR2 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, TECPR2 protein abundance shows 23,259 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, and GBM as cancer lineages where TECPR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TECPR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TECPR2 survival associations across molecular data types. TECPR2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TECPR2 RNA expression–survival associations across cancer types. High TECPR2 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, BRCA, ESCA, ACC and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TECPR2 RNA expression.
This table summarizes TECPR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TECPR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TECPR2 shows lower tumor expression in BLCA, KICH, BRCA and KIRC and higher tumor expression in LIHC and HNSC. The BLCA box plot shows higher TECPR2 RNA expression in normal versus tumor tissue (log2 FC = −1.585, t-test p = .003).
This table shows molecular features associated with TECPR2 in patient tissues and cancer cell lines. In patient samples, TECPR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TECPR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
